Testing effectiveness (Phase 2)Study completedNCT03909971What this trial is testingLorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaWho this might be right forCarcinoma, Non-Small-Cell Lung Pfizer 109
Not applicableStudy completedNCT04979988What this trial is testingStudy to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese PatientsWho this might be right forALK-positive Non-small-cell Lung Cancer Pfizer 51
Not applicableAvailableNCT04146571What this trial is testingExpanded Access to Ensartinib for Participants With ALK+ NSCLCWho this might be right forNon-Small Cell Lung CancerALK Gene Rearrangement Positive Xcovery Holdings, Inc.
Testing effectiveness (Phase 2)UnknownNCT04074993What this trial is testingBrigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysWho this might be right forNon Small Cell Lung Cancer JI-YOUN HAN 35
Not applicableUnknownNCT06234579What this trial is testingLongitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)Who this might be right forALK Gene MutationNSCLC Stage IVALK Sensitizing Mutation Fondazione Policlinico Universitario Agostino Gemelli IRCCS 108
Early research (Phase 1)Ended earlyNCT03087448What this trial is testingCeritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer University of California, San Francisco 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT03753685What this trial is testingX-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesWho this might be right forNonsmall Cell Lung CancerBrain Metastases Fudan University 27
Testing effectiveness (Phase 2)Ended earlyNCT02134912What this trial is testingS1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibWho this might be right forAdenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung Cancer+1 more SWOG Cancer Research Network 1
Early research (Phase 1)Active Not RecruitingNCT05441956What this trial is testingTGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer Shenzhen TargetRx Co., Ltd. 198
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539What this trial is testingNeoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer West China Hospital 33
Testing effectiveness (Phase 2)UnknownNCT03389815What this trial is testingA Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsWho this might be right forAdvanced Solid Tumor, Non-small Cell Lung Cancer Qilu Pharmaceutical Co., Ltd. 48
Not applicableEnded earlyNCT02554591What this trial is testingGenomic Landscape of CeritinibWho this might be right forCarcinoma, Non-Small-Cell LungNon-small Lung CancerNon-Small Cell Lung Cancer Washington University School of Medicine 6
Post-approval studies (Phase 4)Not Yet RecruitingNCT06785584What this trial is testingEfficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical StudyWho this might be right forALK-positive Advanced NSCLCALK-positive Non-small Cell Lung Cancer (NSCLC)MPR+1 more Fujian Medical University Union Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05178511What this trial is testingEnsatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI ResistanceWho this might be right forThe Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients Li Zhang, MD 40
Early research (Phase 1)Looking for participantsNCT06225427What this trial is testingGilteritinib for the Treatment of ALK NSCLCWho this might be right forLung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8 University of Michigan Rogel Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02767804What this trial is testingEXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsWho this might be right forNon-small Cell Lung Cancer Xcovery Holdings, Inc. 290
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010What this trial is testingAlectinib in Neo-adjuvant Treatment of Stage III NSCLCWho this might be right forNon Small Cell Lung Cancer Gruppo Oncologico Italiano di Ricerca Clinica 33
Not applicableStudy completedNCT03271554What this trial is testingTreatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaWho this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 355
Large-scale testing (Phase 3)UnknownNCT04009317What this trial is testingStudy of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Who this might be right forALK-positive NSCLC Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Testing effectiveness (Phase 2)UnknownNCT05482087What this trial is testingXZP-3621 in Chinese Patients With ALK Positive NSCLCWho this might be right forALK-positive NSCLC Xuanzhu Biopharmaceutical Co., Ltd. 190